Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Abbott
ClinicalTrials.gov Identifier:
NCT01346319
First received: April 20, 2011
Last updated: November 1, 2011
Last verified: September 2011

April 20, 2011
November 1, 2011
April 2011
September 2011   (final data collection date for primary outcome measure)
To determine the pharmacokinetics of testosterone after multiple oral doses of ABT-SLV361 in hypogonadal males [ Time Frame: During confinement ] [ Designated as safety issue: No ]
Blood sample results for testosterone
  • To determine the pharmacokinetics of testosterone after multiple oral doses of ABT-SLV361 in hypogonadal males [ Time Frame: During the 19 days of confinement ] [ Designated as safety issue: No ]
    Blood sample results for testosterone
  • Vital signs [ Time Frame: During the 19 days of confinement ] [ Designated as safety issue: Yes ]
    Blood pressure, pulse and temperature
  • Physical exam [ Time Frame: During the 19 days of confinement ] [ Designated as safety issue: Yes ]
    Medical history and system directed physical exam
  • Chemical safety parameters [ Time Frame: During the 19 days of confinement ] [ Designated as safety issue: Yes ]
    Chemistry, hematology and urinalysis
Complete list of historical versions of study NCT01346319 on ClinicalTrials.gov Archive Site
To determine the pharmacokinetic of testosterone undecanoate after multiple oral doses of ABT-SLV361 in hypogonadal males [ Time Frame: During confinement ] [ Designated as safety issue: No ]
Blood sample results for testosterone undecanoate
To determine the pharmacokinetic of testosterone undecanoate after multiple oral doses of ABT-SLV361 in hypogonadal males [ Time Frame: Blood sample results for testosterone undecanoate ] [ Designated as safety issue: No ]
During the 19 days of confinement
Not Provided
Not Provided
 
Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.
A Randomized Double-Blind, Placebo-controlled Dose Escalating Study of the Pharmacokinetics, Safety and Tolerability of Testosterone Undecanoate (ABT-SLV361) in Hypogonadal Males

Phase 1 Dose Escalating Study of the safety, tolerability and pharmacokinetics of testosterone in hypogonadal males.

M12-778 is a rising multiple dose, randomized, double blind, placebo controlled single center study. It will have 5 dose groups of 20 subjects in dose groups 1,2 and 3 and 24 subjects in dose groups 4 and 5; a total of 84 subjects . There will be a 7 day period between dose groups 1,2 and 3 to assess the safety of increasing to the next dose. Dose groups of 4 and 5 will be run in parallel. Subjects will be confined in center for 20 days for dose groups 1,2 and 3 and 33 days for dose groups 4 and 5.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Hypogonadal Males
  • Drug: ABT-SLV361
    For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
    Other Name: ABT-SLV361
  • Drug: placebo
    For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
  • Active Comparator: Testosterone undecanoate
    Intervention: Drug: ABT-SLV361
  • Placebo Comparator: Placebo
    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
0
September 2011
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria

  1. Serum total testosterone < 300 ng/dL based on two blood samples obtained between 6 and 10 AM on two separate occasions at least 48 hours apart. Previously documented total testosterone results obtained within 6 weeks of Study Day -2 may be used during screening for subjects not currently on androgen replacement therapy, or following washout of androgen replacement therapy.
  2. Subjects naïve to androgen replacement or washout of 12 weeks following intramuscular androgen injections; 4 weeks following topical or buccal androgens; and 3 weeks following oral androgens. Washout should be completed by Study Day -2.
  3. Subject is judged to be in good general health as determined by the principal investigator based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12 lead electrocardiogram (ECG) performed at Screening.
  4. Must voluntarily sign and date each informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.

Exclusion Criteria

  1. History of significant sensitivity or allergy to any drug, including androgens, castor oil or product excipients.
  2. Previous history or current or suspected prostate or breast cancer, and/or previous history of cancer (except basal cell carcinoma of the skin).
  3. Subjects not on a stable medication regimen for at least three months for the treatment of a chronic condition such as hypertension, hyperlipidemia or diabetes mellitus.
  4. Use of known inhibitors (e.g., ketoconazole) or inducers (e.g., dexamethasone, phenytoin, rifampin, carbamazepine) of cytochrome P450 3A (CYP3A) within 30 days prior to study drug administration and through the end of the study.
  5. Use of any drug within 5 half-lives of the last dose in the past 6 months prior to Study Day -2 without principal investigator and/or sponsor approval.
  6. Receipt of any drug by injection within 30 days or 10 half-lives (which ever is longer) prior to study drug administration without principal investigator and/or sponsor approval.
Male
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01346319
M12-778
No
Abbott
Abbott
Not Provided
Study Director: Bela Denes, MD Abbott
Abbott
September 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP